A Danish medicines repackager has again had its manufacturing certificate yanked by regulators just months after it assured customers that it had resolved its problems to the satisfaction of the Danish Medicines Agency. More: In rapid turnaround, regulators again pull
read moreFive more lawmakers are piling on Allergan for the company’s controversial tribal licensing deal. In a letter to CEO Brent Saunders, they’re requesting more information on the “unprecedented” deal. More: Senators blast Allergan's tribal deal, social contract as 'hypocrisy' Source:
read moreKeryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level. More: Keryx looks to
read moreUS regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600 More: FDA OKs Roche’s Zelboraf for rare blood disease Source: News
read moreBayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma. More: NICE turns down Bayer’s Stivarga for liver cancer Source: News
read moreGlaxoSmithKline is seeking permission to market its asthma biologic mepolizumab for the treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in the US. More: GSK files Nucala for COPD Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals